entertainment -WSS

entertainment

author：knowledge 2025-09-28 23:10:50 - browse：97942

A gene therapy study, halted when four children with a rare neuromuscular disorder died after treatment, showed enough promise to merit finding a path forward, according to the medicine’s manufacturer.

The treatment, made by the Japanese pharmaceutical company Astellas, led to severe and fatal liver problems for four of the 24 treated children with X-linked myotubular myopathy, or XLMTM, a genetic disease that severely degrades muscle function and kills most patients before the age of 10. Three died in 2020; the fourth died a year later.

In an analysis of its clinical trial, published in Lancet Neurology on Wednesday, Astellas observed dramatic benefits in the study’s surviving patients and a potential explanation for the deaths that derailed the trial. The hope, for Astellas and for families affected by XLMTM, is that the company can find a safe way to proceed and convince the Food and Drug Administration to allow it to resume development.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： CMS got Medicare Advantage quality rating wrong, judge rules

hotspot

WSS

Elevance PBM president out as customers face prescription chaos

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

Elevance PBM president out as customers face prescription chaos

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Plastic surgeons increase patient psychiatric screenings

Neuroscience’s long legacy of racism

hotspot

entertainment

Wikipedia

New air purifier tech could be key to improving indoor air quality

Anthony Fauci pushes back on GOP claims during Covid hearing

After affirmative action ruling, medical educators look to 'holistic review'

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Cancer drug shortages should be causing more outrage

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Medical leaders decry Supreme Court decision on affirmative action

Stop the failed accountable care organization experiment

Hepatitis C has a cure — but many Americans still lack access to it

Intermittent fasting comes with a heart risk? Not so fast

Wikipedia

Data don't support strong claims for Covid

Orchard's therapy for neuron disease in children wins FDA approval

Data don't support strong claims for Covid

App could help diagnose ear infections more accurately — and at home

Asbestos, a deadly carcinogen, banned by EPA

Eli Lilly’s Zepbound improved liver scarring in mid

knowledge

focus

hotspot

leisure time